NCT07216534 Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants
| NCT ID | NCT07216534 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Hematopoietic and Lymphatic System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2026-09-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial compares virtual reality viewing of an unaltered streetscape versus a digitally manipulated opposite streetscape to assess the psychosocial response in participants. Visible measures of neighborhood factors might be associated with health outcomes and risk factors of those outcomes. Short-term exposure to virtual reality environments representing very high or very low levels of neighborhood physical disorder - presence or absence of garbage/litter, presence or absence of graffiti, presence or absence of an abandoned building, presence or absence of large dumpsters, poor or very well-kept building conditions, poor or very well-kept yard conditions, poor or very well-kept road verge conditions may be a safe and effective way to assess psychosocial response in participants.
Eligibility Criteria
Inclusion Criteria: * Adults 18+ * Must currently live (4+ night/week) at the residence being studied. Only one resident per household will be selected * Must understand and be able to read English * Must agree to have residence photographed * Must be able to wear a VR head mounted display * Must live in neighborhood that has been selected for study * Must be willing and able to attend an approximately 2 hour in-person visit on Ohio State University (OSU) campus Exclusion Criteria: * Pregnant women * Visual or mobility impairment * Cannot have epilepsy or other condition that would inhibit them from being able to use a VR headset
Contact & Investigator
The Ohio State University Comprehensive Cancer Center
✉ OSUCCCClinicaltrials@osumc.edu📞 800-293-5066
Jesse Plascak, PhD, MPH
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT07216534 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphatic System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07216534 currently recruiting?
Yes, NCT07216534 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT07216534 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT07216534 clinical trial?
NCT07216534 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Jesse Plascak, PhD, MPH at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 32 participants.